Global Schizophrenia Therapeutics Market 2017-2021

Global schizophrenia therapeutics market forecast

Research analysis on the global schizophrenia therapeutics market identifies that the emergence of enhanced next-generation products will have a positive impact on the market’s growth. Chlorpromazine, haloperidol, and fluphenazine are some of the first antipsychotic drugs, which are also known as first-generation or typical antipsychotic drugs. These drugs are not selective in nature and act at the D2 receptor site on the mesolimbic pathway. They are also used to block the D2 receptors present in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. However, with the introduction of second-generation antipsychotic drugs, first-generation drugs were largely out of practice. Clozapine, risperidone, olanzapine, quetiapine, and ziprasidone are some of the second-generation drugs, which are also known as atypical antipsychotic drugs. Researchers are increasingly focusing on the development of newer antipsychotic drugs with lesser side effects and enhanced efficacy. This encourages them to continuously manufacture enhanced antipsychotic drugs. According to the schizophrenia therapeutics industry analysis, this market will grow at a CAGR of close to 2% by 2021.

Get A Free Sample 

The increasing use of long-acting injectable (LAI) antipsychotic drugs is one of the key trends that will propel the growth prospects for the global schizophrenia therapeutics market for the next four years. The LAI antipsychotics drugs can attain higher efficacy in negative and cognitive predominant patients. They improve patient compliance because they are associated with both reduced hospitalization rates and reduced care costs.

Competitive landscape and key vendors

The schizophrenia drugs market is fragmented due to the presence of many leading players. These vendors are increasingly competing against each other based on factors such as emerging indications or applications, major patent expiries, and the rising prevalence of mental disorder in the developed and developing countries. Vendors are losing their market revenue because the market is witnessing the patent expiry of major drugs over the last few years such as ZYPREXA by Eli Lilly and Seroquel by AstraZeneca.

Key vendors in this market are 

• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson

Other prominent vendors in the market include Alkermes and Bristol-Myers Squibb.

Segmentation by drug-class and analysis of the schizophrenia therapeutics market

• First-generation antipsychotic drugs
• Second-generation antipsychotic drugs
• Third-generation antipsychotic drugs

The second-generation antipsychotic drugs segment accounted for the majority of market shares during 2016 because these drugs involve fewer side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improve the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This, in turn, will boost the segment’s growth throughout the estimated period.

Segmentation by geography and analysis of the schizophrenia therapeutics market

• Americas
• APAC
• EMEA

Based on the schizophrenia therapeutics market overview, the Americas is experiencing sluggish growth due to patent expiry of major drugs such as Geodon, ZYPREXA, ABILIFY, SEROQUEL, and Prozac. However, vendors in the market are increasingly focusing on the development of DMD for schizophrenia. For instance, the American drug-maker AbbVie is taking efforts to develop schizophrenia treatment drug to treat the cognitive impairment associated with schizophrenia. Similarly, Amgen developed the schizophrenia drug AMG 581 for the treatment of schizophrenia and is conducting Phase I trials for the drug.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the schizophrenia therapeutics market size and the growth rate be in 2021?
• What are the key factors driving the global schizophrenia therapeutics market?
• What are the key schizophrenia therapeutics market trends impacting the growth of the market?
• What are the challenges to market growth?
• Who are the key vendors in the global schizophrenia therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global schizophrenia therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global schizophrenia therapeutics market?

Technavio also offers customization on reports based on specific client requirement.